Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy

Li, Changyou; Xu, Jing; Wang, Qi; Geng, Shaoqing; Zheng, Yan; You, Jin Qiang; Li, Zhenfeng; Zou, Xiao Ping

doi:10.3892/ol.2018.8310

Cited by 7 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regularly, PN molecules are secreted from cancerassociated fibroblasts (CAF) and can activate the cancer cells via integrin receptors [3]. PN expression in cancer tissue was significantly correlated to survival of patients in colorectal cancer (CRC) [11], CCA [9] and BCA [12]. In addition, serum PN was also positively correlated with poor prognosis in CRC [13] and CCA [14].…”

Section: Introductionmentioning

confidence: 99%

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Kamolhan

Soni

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote cancer progression including cell survival, metastasis, and chemoresistance. The main objective of this study was to develop an anti-PN peptide from the bacteriophage library to overcome PN effects in breast cancer (BCA) cells. Methods A twelve amino acids bacteriophage display library was used for biopanning against the PN active site. A selected clone was sequenced and analyzed for peptide primary structure. A peptide was synthesized and tested for the binding affinity to PN. PN effects including a proliferation, migration and a drug sensitivity test were performed using PN overexpression BCA cells or PN treatment and inhibited by an anti-PN peptide. An intracellular signaling mechanism of inhibition was studied by western blot analysis. Lastly, PN expressions in BCA patients were analyzed along with clinical data. Results The results showed that a candidate anti-PN peptide was synthesized and showed affinity binding to PN. PN could increase proliferation and migration of BCA cells and these effects could be inhibited by an anti-PN peptide. There was significant resistance to doxorubicin in PN-overexpressed BCA cells and this effect could be reversed by an anti-PN peptide in associations with phosphorylation of AKT and expression of survivin. In BCA patients, serum PN showed a correlation with tissue PN expression but there was no significant correlation with clinical data. Conclusions This finding supports that anti-PN peptide is expected to be used in the development of peptide therapy to reduce PN-induced chemoresistance in BCA.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Kamolhan

Soni

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Finally, periostin may have a role in breast cancer prognostication. In 259 breast cancer patients who underwent surgical and radiation therapy, local recurrence-free survival, distant metastasis-free survival and overall survival were significantly lower in the patients whose tumors expressed periostin as compared to those whose tumors were negative for periostin [90].…”

mentioning

confidence: 93%

Vitamin K effects in human health: new insights beyond bone and cardiovascular health

et al. 2019

View full text Add to dashboard Cite

Vitamin K is a cofactor for the function of the enzyme γ-glutamyl carboxylase, necessary for the activation of multiple vitamin K dependent-proteins. Vitamin K dependent-proteins (VKDPs) have important roles in bone health, vascular health, metabolism, reproduction as well as in cancer progression. Vitamin K deficiency is common in different conditions, including kidney disease, and it may influence the activity of VKDPs. This review discusses vitamin K status in human health and the physiologic and pathologic roles of VKDPs, beyond the established effects in skeletal and cardiovascular health.

show abstract

“…, CCA [9] and BCA [12]. In addition, serum PN was also positively correlated with poor prognosis in CRC [13] and CCA [14].…”

mentioning

confidence: 87%

Development of an Engineered Peptide Antagonist against Periostin to Overcome Doxorubicin Resistance in Breast Cancer

Kamolhan

Soni

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote cancer progression including cell survival, metastasis, and chemoresistance. The main objective of this study was to develop an anti-PN peptide from the bacteriophage library to overcome PN effects in breast cancer (BCA) cells. Methods: A twelve amino acids bacteriophage display library was used for biopanning against the PN active site. A selected clone was sequenced and analyzed for peptide primary structure. A peptide was synthesized and tested for the binding affinity to PN. PN effects including a proliferation, migration and a drug sensitivity test were performed using PN overexpression BCA cells or PN treatment and inhibited by an anti-PN peptide. An intracellular signaling mechanism of inhibition was studied by western blot analysis. Lastly, PN expressions in BCA patients were analyzed along with clinical data. Results: The results showed that a candidate anti-PN peptide was synthesized and showed affinity binding to PN. PN could increase proliferation and migration of BCA cells and these effects could be inhibited by an anti-PN peptide. There was significant resistance to doxorubicin in PN-overexpressed BCA cells and this effect could be reversed by an anti-PN peptide in associations with phosphorylation of AKT and expression of survivin. In BCA patients, serum PN showed a correlation with tissue PN expression but there was no significant correlation with clinical data. Conclusions: This finding supports that anti-PN peptide is expected to be used in the development of peptide therapy to reduce PN-induced chemoresistance in BCA.

show abstract

Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy

Cited by 7 publications

References 23 publications

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Vitamin K effects in human health: new insights beyond bone and cardiovascular health

Development of an Engineered Peptide Antagonist against Periostin to Overcome Doxorubicin Resistance in Breast Cancer

Contact Info

Product

Resources

About